Evidence map›Paper›PMID 34144852›Full record

ArticleVaccine2022

Multiple cohort HPV vaccination in Zimbabwe: 2018-2019 program feasibility, awareness, and acceptability among health, education, and community stakeholders.

Julie R Garon, Aluwisio Mukavhi, Maxwell Rupfutse, Shakia Bright, Timothy Brennan, Portia Manangazira, Qian An, Anagha Loharikar

Open access · hybridAbstract read
In one paragraph

Article in Vaccine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Vaccination Effectiveness against Human Papillomavirus in Kazakhstan.Asian Pacific journal of cancer prevention : APJCP · 2024
    Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Julie R GaronCDC Foundation, USA; Centers for Disease Control and Prevention, Global Immunization Division, Atlanta, USA. Electronic address: jgaron@cdc.gov.
Aluwisio MukavhiZIMSTAT, Zimbabwe.
Maxwell RupfutseWorld Health Organization, Zimbabwe.
Shakia BrightCenters for Disease Control and Prevention, Global Immunization Division, Atlanta, USA.
Timothy BrennanCDC Foundation, USA.
Portia ManangaziraEpidemiology and Disease Control, Zimbabwe Ministry of Health and Child Care, Zimbabwe.
Qian AnCenters for Disease Control and Prevention, Global Immunization Division, Atlanta, USA.
Anagha LoharikarCenters for Disease Control and Prevention, Global Immunization Division, Atlanta, USA.
Centers for Disease Control and Prevention · USCDC Foundation · USMinistry of Health and Child Welfare · ZWWorld Health Organization - Zimbabwe · ZW

Funding

Intramural CDC HHS CC999999World Health Organization 001
6 · The paper itself

Abstract

introductionZimbabwe introduced human papillomavirus (HPV) vaccine nationally in May 2018, targeting multiple cohorts (girls aged 10-14 years) through a school-based vaccination campaign. One year later, the second dose was administered to the multiple cohorts concurrently with the first dose given to a new single cohort of girls in grade 5. We conducted cross-sectional surveys among health workers, school personnel, and community members to assess feasibility of implementation, training, social mobilization, and community acceptability.

methodsThirty districts were selected proportional to the volume of the HPV vaccine doses delivered in 2018; two health facilities were randomly selected within each district. One health worker, school health coordinator, village health worker, and community leader were surveyed at each selected health facility and surrounding area during January-February 2020, using standard questionnaires. Descriptive analysis was completed across groups.

resultsThere were 221 interviews completed. Over 60% of health workers reported having enough staff to carry out vaccination sessions in schools while maintaining routine vaccination services in health facilities. All school health coordinators felt the HPV vaccine should be delivered in schools in the future. Knowledge of the correct target cohort eligibility decreased from 91% in 2018 to 50% in 2020 among health workers. Understanding of HPV infection and use of HPV vaccine for cervical cancer prevention was above 90% for all respondents. Forty-two percent of respondents reported hearing rumors about the HPV vaccine, primarily regarding infertility and safety.

conclusionsFindings demonstrate the presence of highly knowledgeable staff at health facilities and schools, strong community acceptance, and a school-based HPV program considered feasible to implement in Zimbabwe. However, misunderstandings regarding target eligibility and rumors persist, which can impact vaccine uptake and coverage. Continued social mobilization efforts to maintain community demand and training on eligibility were recommended. Integration, partnerships, and resource mobilization are also needed to ensure program sustainability.

Indexed as

Papillomavirus InfectionsPapillomavirus VaccinesUterine Cervical NeoplasmsCommunity Health WorkersCross-Sectional StudiesFeasibility StudiesFemaleHealth Knowledge, Attitudes, PracticeHumansImmunization ProgramsPatient Acceptance of Health CareVaccinationZimbabwePapillomavirus VaccinesHuman papillomavirus (HPV) vaccineMultiple cohortSchool-based vaccinationVaccine introductionZimbabwe

Identifiers

PMID34144852
PMCPMC10367138
OpenAlexW3166849035

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.